BCYC

Bicycle Therapeutics plc [BCYC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BCYC Stock Summary

Top 10 Correlated ETFs

BCYC


Top 10 Correlated Stocks

BCYC


In the News

01:07 29 Mar 2024 BCYC

2 More Potential Biotech Buyout Targets

M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.

04:35 29 Mar 2024 BCYC

Bicycle Therapeutics to Present at the AACR Annual Meeting 2024

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of three abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego on April 5-10. Poster Presentation Details: Title: Bicycle Toxin Conjugates® for the.

09:05 29 Mar 2024 BCYC

Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up

Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladder cancer drug, BT8009, with the potential to support its accelerated approval. The stock rises 9%.

08:20 29 Mar 2024 BCYC

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?

Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

02:19 29 Mar 2024 BCYC

Why Shares of Bicycle Therapeutics Were Rising on Monday

Bicycle Therapeutics has 14 programs in its pipeline. The company is a clinical-stage biotech.

07:00 29 Mar 2024 BCYC

Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023, at 10:10 a.m. ET. A live webcast of the fireside chat will be accessible in the Investors & Media s.

07:07 29 Mar 2024 BCYC

Bicycle Therapeutics: Decent Upside Opportunity, Mid-Stage Data Readouts Due

Bicycle Therapeutics is an intriguing play in the drug development space. Using its fully synthetic short peptides, the company has developed two mid-stage oncology assets that have achieved some results of interest in urothelial / ovarian cancers. The company also has numerous potentially lucrative co-development opportunities with the likes of Roche, Novartis, Ionis Pharmaceuticals.

08:08 29 Mar 2024 BCYC

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock?

Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

06:40 29 Mar 2024 BCYC

Why Bicycle Therapeutics Stock Raced Ahead Today

The U.K.-based biotech announced a fresh offering of its ADSes. It's seeking to net around $187 million in proceeds with the issue.

07:16 29 Mar 2024 BCYC

Bicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs Yet

BCYC's distinction is that it is founded by a Nobel laureate. However, unless it can differentiate its product's efficacy from that of mAbs, that may be its only distinction.

BCYC Financial details

Company Rating
Sell
Market Cap
1.08B
Income
-180.66M
Revenue
26.98M
Book val./share
8.74
Cash/share
12.41
Dividend
-
Dividend %
-
Employees
284
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-4.72
Forward P/E
-4.45
PEG
-1.35
P/S
29.71
P/B
1.83
P/C
2.01
P/FCF
-15.38
Quick Ratio
8.45
Current Ratio
8.65
Debt / Equity
0.12
LT Debt / Equity
0.11
-
-
EPS (TTM)
-5.13
EPS next Y
-5.59
EPS next Q
-1.25
EPS this Y
33.68%
EPS next Y
8.89%
EPS next 5Y
-73.56%
EPS last 5Y
12.9%
Revenue last 5Y
14.34%
Revenue Q/Q
-0.39%
EPS Q/Q
-7.94%
-
-
-
-
SMA20
-
SMA50
38.89%
SMA100
66.67%
Inst Own
66.65%
Inst Trans
0.82%
ROA
-25%
ROE
-56%
ROC
-0.3%
Gross Margin
100%
Oper. Margin
-676%
Profit Margin
-651%
Payout
-
Shs Outstand
42.43M
Shs Float
41.93M
-
-
-
-
Target Price
70.5
52W Range
12.54-28.91
52W High
-11.07%
52W Low
+107.5%
RSI
57
Rel Volume
0.56
Avg Volume
354.58K
Volume
200.28K
Perf Week
-3.68%
Perf Month
10.67%
Perf Quarter
15.71%
Perf Half Y
25.13%
-
-
-
-
Beta
0.893
-
-
Volatility
0.35%, 0.87%
Prev Close
0%
Price
24.9
Change
1.22%

BCYC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.250.540.470.490.76
Net income per share
-2.77-2.66-2.67-3.8-5.08
Operating cash flow per share
-2.59-0.93-0.59-2.9-1.7
Free cash flow per share
-2.73-0.99-0.67-3.54-1.79
Cash per share
8.347.117.511.4314.79
Book value per share
8.444.9913.829.1310.42
Tangible book value per share
8.444.9913.829.1310.42
Share holders equity per share
8.444.9913.829.1310.42
Interest debt per share
0.170.851.891.611.35
Market cap
104.16M343.67M1.53B877.96M643.51M
Enterprise value
13.93M223.45M1.13B583.13M162.04M
P/E ratio
-3.4-6.74-22.83-7.79-3.56
Price to sales ratio
7.5533.08130.4260.723.85
POCF ratio
-3.64-19.32-103.12-10.2-10.61
PFCF ratio
-3.45-18.1-90.67-8.35-10.12
P/B Ratio
1.123.64.413.241.73
PTB ratio
1.123.64.413.241.73
EV to sales
1.0121.5196.7140.326.01
Enterprise value over EBITDA
-0.53-4.36-17.27-5.26-0.96
EV to operating cash flow
-0.49-12.56-76.46-6.77-2.67
EV to free cash flow
-0.46-11.77-67.24-5.55-2.55
Earnings yield
-0.29-0.15-0.04-0.13-0.28
Free cash flow yield
-0.29-0.06-0.01-0.12-0.1
Debt to equity
0.020.170.130.160.12
Debt to assets
0.020.10.090.110.08
Net debt to EBITDA
3.432.346.022.662.85
Current ratio
11.816.7312.656.928.08
Interest coverage
0-113.7-21.99-34.88-58.21
Income quality
0.930.350.220.760.34
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.052.812.773.422.22
Research and developement to revenue
1.853.193.845.645.8
Intangibles to total assets
00000
Capex to operating cash flow
0.050.070.140.220.05
Capex to revenue
-0.11-0.12-0.17-1.31-0.11
Capex to depreciation
-1.62-0.94-1.44-5.15-0.45
Stock based compensation to revenue
0.220.631.031.851.2
Graham number
22.9417.2928.7927.9434.5
ROIC
-0.27-0.46-0.16-0.35-0.45
Return on tangible assets
-0.28-0.32-0.14-0.27-0.3
Graham Net
7.294.2412.537.268.99
Working capital
95.33M132.59M422.32M316.04M492.33M
Tangible asset value
93.2M95.46M346.25M270.78M370.93M
Net current asset value
87.15M90.03M325.02M229.56M337.46M
Invested capital
0.020.170.130.160.12
Average receivables
9.23M10.89M13.27M16.56M22.62M
Average payables
1.92M1.66M2.04M4.6M9.76M
Average inventory
0.50.500.50.5
Days sales outstanding
188.97514.06371.65535.2325.26
Days payables outstanding
27.8515.0322.13640.75724.85
Days of inventory on hand
00000
Receivables turnover
1.930.710.980.681.12
Payables turnover
13.124.2816.490.570.5
Inventory turnover
25.54M003.69M0
ROE
-0.33-0.53-0.19-0.42-0.49
Capex per share
-0.14-0.06-0.08-0.64-0.08

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.110.160.380.140.13
Net income per share
-1.01-1.3-1.41-1.26-1.16
Operating cash flow per share
-1.02-1.551.13-0.03-1.11
Free cash flow per share
-1.07-1.621.12-0.04-1.12
Cash per share
11.419.7911.2814.4612.41
Book value per share
9.118.17.2910.518.74
Tangible book value per share
9.118.17.2910.518.74
Share holders equity per share
9.118.17.2910.518.74
Interest debt per share
1.521.681.591.171.08
Market cap
879.46M638.14M770.49M795.09M766.94M
Enterprise value
584.63M393.79M477.13M268.69M285.47M
P/E ratio
-7.33-4.08-4.52-3.98-3.91
Price to sales ratio
276.13130.3467.6148.56143.86
POCF ratio
-29.02-13.7522.6-775.7-16.22
PFCF ratio
-27.69-13.1522.78-520.69-16.2
P/B Ratio
3.252.623.51.912.07
PTB ratio
3.252.623.51.912.07
EV to sales
183.5680.4341.8650.253.55
Enterprise value over EBITDA
-19.77-10.13-11.62-6.05-6.14
EV to operating cash flow
-19.29-8.4813.99-262.14-6.04
EV to free cash flow
-18.41-8.1214.11-175.96-6.03
Earnings yield
-0.03-0.06-0.06-0.06-0.06
Free cash flow yield
-0.04-0.080.040-0.06
Debt to equity
0.160.20.210.110.12
Debt to assets
0.110.120.10.070.08
Net debt to EBITDA
9.976.297.1511.8510.36
Current ratio
6.927.195.658.658.08
Interest coverage
-39-51.74-52.51-62.4-66.14
Income quality
1.011.19-0.80.020.96
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.352.961.332.912.82
Research and developement to revenue
7.766.583.497.458.38
Intangibles to total assets
00000
Capex to operating cash flow
0.050.05-0.010.490
Capex to revenue
-0.45-0.43-0.02-0.09-0.01
Capex to depreciation
-1.04-1.35-0.17-0.3-0.03
Stock based compensation to revenue
1.741.850.721.391.47
Graham number
14.3815.4115.2117.2715.09
ROIC
-0.1-0.13-0.15-0.11-0.13
Return on tangible assets
-0.07-0.09-0.09-0.08-0.08
Graham Net
7.245.524.969.167.54
Working capital
316.04M328.26M336.16M533.3M492.33M
Tangible asset value
270.78M243.16M220.1M416.02M370.93M
Net current asset value
229.56M195.62M174.36M380.38M337.46M
Invested capital
0.160.20.210.110.12
Average receivables
16.29M48.86M67.24M37.63M20.66M
Average payables
6.76M4.64M4.03M6.87M10.77M
Average inventory
0.510.500
Days sales outstanding
599.261.41K457.81290.53405.84
Days payables outstanding
417.13161.14286.31454.93703.97
Days of inventory on hand
00000
Receivables turnover
0.150.060.20.310.22
Payables turnover
0.220.560.310.20.13
Inventory turnover
1.4M1.57M000
ROE
-0.11-0.16-0.19-0.12-0.13
Capex per share
-0.05-0.07-0.01-0.010

BCYC Frequently Asked Questions

What is Bicycle Therapeutics plc stock symbol ?

Bicycle Therapeutics plc is a GB stock and trading under the symbol BCYC

Is Bicycle Therapeutics plc buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $70.5. The lowest prediction is $65 and the highest is $76

What is BCYC stock prediction ?

What is Bicycle Therapeutics plc stock quote today ?

Bicycle Therapeutics plc stock price is $24.9 today.

Is Bicycle Therapeutics plc stock public?

Yes, Bicycle Therapeutics plc is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap